Patients receiving TNF-α inhibitor treatment should be closely monitored for serious infections and should be educated about how to avoid infectious complications.[38] Although rare, clinicians need to closely monitor for malignancy, and induction of autoimmune diseases (psoriasis, lupus) in patients receiving anti-TNF agents. The gene discussed is TNF; the disease is autoimmune disease.